Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Infinity Pharmaceuticals Inc INFIQ

Healthcare Biotechnology
Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K... see more

Recent & Breaking News (GREY:INFIQ)

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire August 20, 2023

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire August 18, 2023

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Infinity Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - INFI

Newsfile August 18, 2023

INFINITY ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Infinity Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Business Wire August 18, 2023

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile August 18, 2023

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Infinity Pharmaceuticals, Inc. (INFI) Investors

Business Wire August 18, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire August 17, 2023

Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Applied Infinity Pharmaceuticals, Inc. (INFI)

Business Wire August 17, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Infinity Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile August 17, 2023

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Infinity Pharmaceuticals, Inc. (INFI) Investors

Business Wire August 17, 2023

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Infinity Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - INFI

Business Wire August 17, 2023

Infinity Pharmaceuticals Announces Value Preservation and Maximization Plan

Business Wire July 25, 2023

Infinity Pharmaceuticals Announces Termination of Merger Agreement with MEI Pharma

Business Wire July 24, 2023

Infinity Pharmaceuticals Announces Stockholder Approval of Merger with MEI Pharma

Business Wire July 14, 2023

Infinity Pharmaceuticals Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck (SCCHN)

Business Wire July 10, 2023

ISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.

Business Wire July 5, 2023

MEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology Candidates

Business Wire June 15, 2023

INFINITY PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Infinity Pharmaceuticals, Inc. - INFI

Business Wire June 14, 2023

SHAREHOLDER ALERT: Weiss Law Reminds MPB, CVT, XM, and INFI Shareholders About Its Ongoing Investigations

PR Newswire May 3, 2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TCFC, INDT, PTRS, INFI

PR Newswire April 27, 2023